1. Home
  2. CTNM vs BETR Comparison

CTNM vs BETR Comparison

Compare CTNM & BETR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

HOLD

Current Price

$13.45

Market Cap

480.5M

Sector

N/A

ML Signal

HOLD

Logo Better Home & Finance Holding Company

BETR

Better Home & Finance Holding Company

HOLD

Current Price

$47.45

Market Cap

538.7M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTNM
BETR
Founded
2009
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
480.5M
538.7M
IPO Year
2024
N/A

Fundamental Metrics

Financial Performance
Metric
CTNM
BETR
Price
$13.45
$47.45
Analyst Decision
Buy
Buy
Analyst Count
4
1
Target Price
$19.00
$40.00
AVG Volume (30 Days)
307.8K
584.1K
Earning Date
05-13-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
0.46
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$55.02
Revenue Next Year
N/A
$65.66
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.35
$10.81
52 Week High
$16.33
$94.06

Technical Indicators

Market Signals
Indicator
CTNM
BETR
Relative Strength Index (RSI) 50.99 65.83
Support Level $10.17 $41.87
Resistance Level $14.20 $51.16
Average True Range (ATR) 0.72 3.81
MACD 0.10 0.92
Stochastic Oscillator 61.13 96.77

Price Performance

Historical Comparison
CTNM
BETR

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

About BETR Better Home & Finance Holding Company

Better Home & Finance Holding Co is a technology-enabled homeownership company that provides mortgage, home equity, and related services through a digital platform. The company operates through two reportable segments: Home Finance, which focuses on residential mortgage origination, including purchase, refinance, and home equity products, generating revenue mainly from loan sales; and Banking, which, through its U.K. subsidiary Birmingham Bank, offers a range of financial products and services to consumers and small businesses. It generates the majority of its revenue from the Home Finance segment.

Share on Social Networks: